|
|
Article: Neurocrine Reports Positive Results for the First Indiplon Phase III Trial In Elderly Patients With Chronic Insomnia; Immediate Release Formulation Demonstrated Statistically Significant Improvements in Sleep Initiation and Sleep Quality.
- Article from:
- PR Newswire
- Article date:
- February 19, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Neurocrine Biosciences, Inc. today announced positive results from its Phase III clinical trial with two doses (5 mg and 10 mg) of the immediate release formulation of indiplon, achieving statistically significant results in elderly patients with chronic insomnia. Results of the primary endpoint for this study, Latency to Sleep Onset (LSO) or the amount of time it took patients to fall asleep, as measured by patient self reported outcomes was statistically significant for both doses (p
"We are pleased with the first Phase III clinical trial results demonstrating that indiplon immediate release formulation is safe and effective in treating elderly patients who experience ...